The movement of the XLV in recent weeks suggests that it may be an outperforming sector in the weeks ahead.
In a market filled with charts without a clear stop, ORCL offers that.
Oracle's acquisition bid today for CERN of about $28.3B certainly helped us get there.
ZTS is in a longer-term uptrend that should continue when the weakness in the broader market subsides.
I like the risk/reward set up now.
With Chinese tech stocks selling off and inflation worrying even the Bank of Japan, there are multiple Asia-specific reasons for the decline.
We now have two new price targets.
Let's check out the charts of this name that will be splitting into three companies.
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
Here's our next price target.